(30) Priority Data:

08/452,846



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

- (51) International Patent Classification 6: WO 96/38464 (11) International Publication Number: **A1** C07J 7/00, 9/00, 41/00 (43) International Publication Date: 5 December 1996 (05.12.96)
- (81) Designated States: CA, JP, European patent (AT, BE, CH, DE, (21) International Application Number: PCT/US96/04851
- 10 April 1996 (10.04.96) (22) International Filing Date:

US

(71) Applicant: LEHIGH UNIVERSITY [US/US]; 526 Brodhead

30 May 1995 (30.05.95)

- Avenue, Bethlehem, PA 18015 (US). (72) Inventor: REGEN, Steven, L.; 1407 Stoneridge Road, Allen-
- town, PA 18104 (US).
- (74) Agent: NOVACK, Michael, R.; Competitive Technologies of PA, Inc., 117 ATLSS Drive, Imbt Labs, Lehigh University, Bethlehem, PA 18015 (US).

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

#### Published With international search report.

(54) Title: ANTIMICROBIAL STEROL CONJUGATES

(57) Abstract

The invention discloses steroid conjugates having structures (I) or (II) where Y is NHCH2CH2CH2CH2NH2, NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, or NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, and each of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> is individually H, OH and OSO<sub>3</sub>H. These conjugates possess antimicrobial properties and are, therefore, useful as antibiotics.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
ΑU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
ВJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	. LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

WO 96/38464 PCT/US96/04851

#### ANTIMICROBIAL STEROL CONJUGATES

Partial financial support in the making of the invention described herein was provided by the National Institutes of Health. In view of providing financial support to the making of the invention described herein, the United States government has certain statutory interests in the invention under 35 USC 200 et seq.

In the course of studies exploring the diversity of antibiotics from animal sources, Michael Zasloff and his colleagues reported on the isolation, structural determination and antimicrobial activity of the first aminosterol antibiotic from stomach extract of the shark *Squalus acanthias* [see Proc. Natl. Acad. Sci., USA 90:1354 (1993), and United States Patent 5,192,756]. This antibiotic was given the name "squalamine" by its discoverers since it was derived from the genus *Squalus*, and its chemical structure was that of an amine. Since its discovery, this naturally-occurring aminosterol has attracted considerable interest because of its potent antimicrobial activity against a broad spectrum of microorganisms.

Chemically, squalamine is  $3\beta$ -N-1-{N-[3-(4-aminobutyl)]-1,3-diaminopropane}- $7\alpha$ ,24 $\zeta$ -dihydroxy- $5\alpha$ -cholestane 24-sulfate, and has the structure:

At the present, the feasibility of obtaining large quantities of this steroidal antibiotic from natural sources appears questionable since only trace amounts are present in the liver and gallbladder of the shark. While a recent

synthesis [see Tetrahedron Letters 35(44):8103 (1994)] has confirmed the structure of squalamine, the 17 steps that are needed to achieve the product, together with a low overall yield (0.36%) and expensive starting material (3 $\beta$ -acetoxy-5-cholenic acid) makes such a route impractical for large-scale production.

Accordingly, there is a need to develop more economical procedures, both in time and cost, for the synthesis of squalamine, and that is where the research effort that led to the making of the compounds described for the first time herein, was directed. This research effort led to the discovery of two and three-step protocols that led to the synthesis of molecules generally sharing a sterol core similar to that of squalamine, but also share its extraordinary antimicrobial properties. Furthermore, the results obtained in the making of the present invention also demonstrate for the first time that the placement of a pendant polyamine (e.g., spermine) and sulfate groups on the A and D rings of a structurally related sterol may be reversed with retention of antimicrobial activity, and that much more accessible squalamine-like compounds, or "mimics", are possible.

By the term "mimic" as used in the description of the present invention is meant an aminosterol compound that contains a cholane ring core (which may be saturated or unsaturated) as found in squalamine. By the term "spermine" as used in the description of the present invention is meant an amino-organic radical having the chemical formula -NH(CH<sub>2</sub>)3NH(CH<sub>2</sub>)4NH(CH<sub>2</sub>)3NH<sub>2</sub>.

Accordingly it is one aspect of the present invention to describe a series of novel squalamine mimics having a pendant polyamine (e.g., spermine) attached to the D ring of the molecule, and a sulfate group attached to the A ring of the molecule.

It is another aspect of the present invention to describe a protocol by which such squalamine mimics may be synthesized.

It is still another aspect of the present invention to provide data showing that the squalamine mimics according to the present invention exhibit potent antibiotic properties against a broad spectrum of microorganisms.

These and other aspects of the present invention may be more fairly understood in conjunction with the following examples and detailed description of the present invention.

Synthesis for the compounds according to the present invention begins with one of seven starting materials, all of which are commercially available. These materials are 23, 24-bisnor-5-cholenic acid-3 $\beta$ -ol; deoxycholic acid; cholic acid; 5 $\beta$ -cholanic acid; 5 $\beta$ -cholanic acid-3 $\alpha$ -ol; 5 $\beta$ -cholanic acid-3 $\alpha$ ,6 $\alpha$ -diol; and 5 $\beta$ -cholanic acid-3 $\alpha$ ,7 $\alpha$ -diol. Structurally these materials are:

23,24-bisnor-5-cholenic acid-3β-ol

СООН

deoxycholic acid

5B-cholanic acid

 $5\beta$ -cholanic acid- $3\alpha$ , $7\alpha$ -diol

Using these materials in the appropriate protocol, compounds according to the present invention may be readily synthesized.

In its broadest interpretation, the compounds according to the present invention are those having the formulae

wherein each R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> may be H, OH or OSO<sub>3</sub>H; and wherein Y is spermine, that is NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>, or NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>.

More specifically, the preferred compounds according to the present invention are those having the following structures.

Compound	X	Y
1	Н	spermine
2	SO <sub>3</sub> H	spermine
3	Н	NHCH2CH2CH2CH2NH2
4	SO <sub>3</sub> H	NHCH2CH2CH2NH2
5	Н	NHCH2CH2NHCH2CH2NHCH2CH2NH2
6	SO <sub>3</sub> H	NHCH2CH2NHCH2CH2NHCH2CH2NH2

Compound	X	Y
7	Н	spermine
8	SO <sub>3</sub> H	spermine
9	Н	NHCH2CH2CH2CH2NH2
10	SO <sub>3</sub> H	NHCH2CH2CH2CH2NH2
11	Н	NHCH2CH2NHCH2CH2NHCH2CH2NH2
12	SO <sub>3</sub> H	NHCH2CH2NHCH2CH2NHCH2CH2NH2

Compound	X	Y
. 13	Н	spermine
14	SO <sub>3</sub> H	spermine
15	Н	NHCH2CH2CH2CH2NH2
16	SO <sub>3</sub> H	NHCH2CH2CH2CH2NH2
17	Н	NHCH2CH2NHCH2CH2NHCH2CH2NH2
18	SO <sub>3</sub> H	NHCH2CH2NHCH2CH2NHCH2CH2NH2

Compound	X	Y
19	Н	spermine
20	Н	NHCH2CH2CH2CH2NH2
21	Н	NHCH2CH2NHCH2CH2NHCH2CH2NH2
22	OSO <sub>3</sub> H	spermine
23	OSO3H	NHCH2CH2CH2CH2NH2
24	OSO <sub>3</sub> H	NHCH2CH2NHCH2CH2NHCH2CH2NH2
25	OH	spermine
26	OH	NHCH2CH2CH2CH2NH2
27	ОН	NHCH2CH2NHCH2CH2NHCH2CH2NH2

Compound	X	Y
28	Н	spermine
29	SO <sub>3</sub> H	spermine
30	Н	NHCH2CH2CH2CH2NH2
31	SO <sub>3</sub> H	NHCH2CH2CH2CH2NH2
32	Н	NHCH2CH2NHCH2CH2NHCH2CH2NH2
33	SO <sub>3</sub> H	NHCH2CH2NHCH2CH2NHCH2CH2NH2

Compound	X	Y
34	Н	spermine
35	SO <sub>3</sub> H	spermine
36	Н	NHCH2CH2CH2CH2NH2
37	SO <sub>3</sub> H	NHCH2CH2CH2CH2NH2
38	Н	NHCH2CH2NHCH2CH2NHCH2CH2NH2
39	SO <sub>3</sub> H	NHCH2CH2NHCH2CH2NHCH2CH2NH2

Individual compounds according to the present invention may be synthesized using the appropriate of three protocols. For example, Compounds such as 1 and 2 may be synthesized according to the following protocol using 23,24-bisnor-5-cholenic acid-3- $\beta$ -ol as the starting material:

More specifically, compounds 1 and 2 were prepared according to the following examples.

## **EXAMPLE I**

The 23,24-Bisnor-3β-ol-5-cholenic Acid N-Hydroxylsuccinimidyl ester shown in the above protocol was synthesized by adding, dropwise, a solution that was prepared from dicyclohexylcarbodiimide (419 mg, 2.04 mmol) plus 5 ml of tetrahydrofuran (THF) to a stirred mixture of 23, 24-bisnor-5-cholenic acid-3β-ol (702 mg, 2.03 mmol) and N-hydroxysuccinimide (235 mg, 2.0 mmol) that was suspended in 30 ml of anhydrous THF maintained at 50° C. The reaction mixture was stirred for an additional 3 hours at 50° C, and left overnight at ambient temperature. The supernatant was separated from the product mixture by filtration and concentrated under reduced pressure. The solid residue that resulted was then dissolved in 40 ml of chloroform and washed, sequentially, with saturated sodium bicarbonate (20 ml), water (20 ml), and brine (10 ml). The chloroform solution was then dried over anhydrous

sodium sulfate and concentrated under reduced pressure. Recrystallization from acetone/petroleum ether gave 577 mg (64%) of 23,24-bisnor-3 $\beta$ -ol-5-cholenic acid N-hydrosylsuccinimidyl ester as a colorless powder, having a melting point of 214-216° C.

Compound 1, the 23,24-Bisnor-3 $\beta$ -ol-5-cholenic acid 3-ol spermine conjugate, was prepared according to the following example II.

## **EXAMPLE II**

To a stirred solution of spermine (68 mg, 0.34 mmol) in 1 ml of anhydrous chloroform was added, dropwise, a solution prepared from 23,24-bisnor-3 $\beta$ -ol-cholenic acid N-hydroxylsuccinimidyl ester (86 mg, 0.19 mmol) plus 4 ml of chloroform over a 5 minute period at ambient temperature. After 30 minutes of reaction, some precipitate appeared in the flask. The heterogenous mixture was stirred overnight, and then transferred to a test tube and washed, sequentially, with 0.1 M NaOH (1 X 2 ml), water (1 X 2 ml), and saturated sodium chloride (1 X 1 ml). After drying over anhydrous potassium carbonate and subsequent solvent removal under reduced pressure, 84 mg of crude product was obtained. Subsequent chromatographic purification using 3.0 g of EM Science silica gel, eluting first with CH3OH and then with CH3OH/30% NH4OH (4/1, v/v), afforded 42 mg of pure product.

Pyridium 23,24-bisnor-3 $\beta$ -ol-5-cholenic Acid N-hydroxysuccinimidyl ester 3-sulfate was prepared according to the following example.

#### **EXAMPLE III**

To a solution of 23,24-bisnor-3β-ol-5-cholenic acid N-hydrosylsuccinimidyl ester (445 mg, 1.00 mmol) in 20 ml of anhydrous chloroform was added, in a single portion, 481 mg (3.03 mmol) of sulfur trioxide/pyridine complex. After stirring the heterogenous mixture for 14 hours at ambient temperature, an additional 20 ml of chloroform was then added, and the mixture cooled to about -10° C, and filtered. Concentration of the filtrate under reduced pressure, followed by recrystallization from acetone/petroleum ether, afforded 355 mg (75%) of Pyridium 23,24-bisnor-3β-ol-5-cholenic Acid N-

hydroxysuccinimidyl ester 3-sulfate as colorless crystals having a melting point of 220-224° C (dec).

Compound 2, the 23,24-bisnor-3 $\beta$ -ol-5-cholenic acid 3-sulfate spermine conjugate was prepared according to the following example.

## **EXAMPLE IV**

To a stirred solution of spermine (215 mg, 1.06 mmol) in 15 ml of anhydrous DMF, which was maintained at 0° C, was added a solution of pyridinium 23,24-bisnor-3 $\beta$ -ol-5-cholenic acid N-hydroxysuccinimidyl ester 3-sulfate (380 mg, 0.63 mmol) in 2.5 ml of anhydrous DMF over a 20 minute period. The mixture was then stirred at ambient temperature for 1 hour, quenched with 20 ml of 0.1 M NaOH, and extracted with 1-butanol (2 X 20 ml). The combined extracts were washed with water (3 X 20 ml) and brine (2 X 20 ml) and dried over sodium sulfate. Removal of solvent under reduced pressure (45° C) afforded 218 mg of solid residue, which was then purified by column chromatography (4.5 g EM Science silica gel, CH3OH/30% NH4OH (4/1, v/v)), and filtration (0.45  $\mu$ m Millipore) to give 140 mg (35%) of compound 2 as a cream-colored solid having a melting point of 212-221 (dec).

Compounds such as compound 7 may be synthesized according to the following protocol using deoxycholic acid as the starting material:

The N-hydroxylsuccinimidyl ester of deoxycholic acid used in the synthesis of compound 7 was prepared in accordance with the following example.

## **EXAMPLE V**

Deoxycholic acid (7.86 g, 20.0 mmol) and N-hydroxysuccinimide (2.38 g, 20.7 mmol) were partially dissolved in 100 ml of anhydrous tetrahydrofuran and then added to a stirred solution that was prepared from dicyclohexylcarbodiimide (4.80 g, 23.3 mmol) plus 20 ml of tetrahydrofuran. The reaction mixture was stirred for an additional 3.5 hours and the dicyclohexyl urea removed by filtration. After the dicyclohexyl urea was washed with tetrahydrofuran, the combined filtrate was concentrated under reduced pressure to about one-third of its initial volume. Chloroform (150 ml) was then added, and the resulting solution was washed with saturated aqueous sodium bicarbonate (2 X 100 ml), water (1 X 100 ml), and saturated sodium chloride (1 X 50 ml). After drying with anhydrous sodium sulfate, the solvent was removed under reduced pressure, and the residue was recrystallized from ethyl acetate/hexanes to give 7.08 g of product in the form of a colorless powder, and having a melting point of 167-169° C.

Compound 7, the deoxycholic acid-spermine conjugate was synthesized according to the following example.

## **EXAMPLE VI**

To a stirred solution of spermine (241 mg, 1.19 mmol) in 4 ml of anhydrous CH2Cl2 was added, over the course of 5 minutes at ambient temperature, a solution that was prepared from the N-hydroxylsuccinimidyl ester of deoxycholic acid (351 mg, 0.71 mmol) 4 ml of CH<sub>2</sub>Cl<sub>2</sub>, and 2 ml of tetrahydrofuran. During this addition, a colorless precipitate appeared, and an additional 4 ml of anhydrous chloroform was added to the reaction mixture. The heterogenous mixture was stirred at ambient temperature overnight, and the solvent was then removed under reduced pressure. The residue was then dissolved in 8 ml of chloroform. The resulting solution was placed in 2 test tubes and these were washed with 0.1 M NaOH (1 X 2 ml), water (1 X 2 ml), and saturated sodium chloride (1 ml). In order to assist phase separation, the mixtures were subjected to centrifugation. The resulting organic phase was then dried over anhydrous potassium carbonate and concentrated under reduced pressure to give 320 mg of solid residue. Subsequent chromatography (5 g of EM Silica gel), using CH<sub>3</sub>OH/30% NH<sub>4</sub>OH (3/2, v/v) as the eluent afforded 255 mg of product which was solidified on drying.

Compounds such as compound 13 may be synthesized according to the following protocol using cholic acid as the starting material:

The N-hydroxylsuccinimidyl ester of cholic acid used as the intermediate in the preparation of compound 13 was synthesized according to the following example.

## **EXAMPLE VII**

To a stirred solution prepared from cholic acid (8.18 g, 20.0 mmol) and N-hydroxysuccinimide (2.7 g, 23.5 mmol) in 80 ml of anhydrous tetrahydrofuran was added a solution that was prepared from dicyclohexylcarbodiimide (4.22 g, 20.5 mmol) and 20 ml of tetrahydrofuran. The mixture was stirred at ambient temperature for 3 hours, and then allowed to stand overnight. The resultant supernatant was concentrated under reduced pressure, and the residue dissolved in 200 ml of chloroform. The solution was then washed with saturated sodium carbonate (2 X 200 ml), water (1 X 100 ml), and saturated sodium chloride (1 X 50 ml). After drying with anhydrous sodium sulfate and solvent removal under reduced pressure, 9.1 g of crude product was obtained which was used without further purification.

Compound 13, the cholic acid-spermine conjugate was synthesized according to the following example.

#### EXAMPLE VIII

To a stirred solution of spermine (196 mg, 0.97 mmol) in 2 ml of anhydrous chloroform was added, over the course of 5 minutes at ambient temperature, a solution prepared from the N-hydroxylsuccinimidyl ester of cholic acid (402 mg, 0.59 mmol) plus 4 ml of chloroform. The homogeneous mixture was then stirred overnight, transferred to two test tubes, and washed with 0.1 M NaOH (1 X 2 ml), water (1 X 2 ml), and saturated sodium chloride (1 ml). After drying with anhydrous potassium carbonate, the solvent was removed under reduced pressure to give 88 mg of crude product. Subsequent purification using 2.0 g of silica, and CH3OH/30% NH4OH (3/2, v/v) as the eluting solvent, afforded 55 mg of the desired conjugate in the form of a colorless, foam-like solid.

The remainder of the compounds according to the present invention may be synthesized using similar protocols with the appropriate starting material having the similar steroidal structure as found in the desired end-product compound.

The antimicrobial activity of the compounds according to the present invention were compared with the results obtained for squalamine as reported in Proc. Nat. Acad. Sci. USA 90:1354 (1993), *supra*, the disclosure of which is incorporated *in toto* herein. The data reported in Table 1 is the minimum inhibitory concentration (MIC) required for complete inhibition of microbial growth. The MIC was determined utilizing known micro-broth dilution methods in which inocula of 10<sup>6</sup>/ml of the test organism were incubated in 0.5X trypticase soy broth at 35° C for 24 hours. The MIC assay data reported in Table 1 is considered by scientists to be an accurate indication for the therapeutic potential of compounds tested when used to treat microbial diseases in animals, particularly in mammals.

K50	>100	>100	>100	>100	>100	12.5	20	25	>100	Q N	>100	100
Candida ; albicans (14053)	4-8	12.5	12.5b	>100 <sup>b</sup>	>100 <sup>b</sup>	3.13 <sup>b</sup>	25b	12.5b	25 <sup>b</sup>	100 <sup>b</sup>	>100 <sup>b</sup>	25b
Serratia marcescens (8100)	>125	>100a	>100a	>100 <sup>a</sup>	>100a	25a	>100a	50a	>100a	>100a	>100ª	>100a
Proteus vulgaris (13315)	4-8	25	>100	>100	>100	3.13	50	25	100	25	>100	20
Staphylococcus aureus (29123)	1-2	6.25	>100	>100	100	1.56	25	12.5	12.5	6.25	100	25
Pseudomonas aeruginosa (27853)	4-8	1 56	3.13	>100	25	3.13	100	6.25	25	3.13	>100	50
E. coli		·	6.25	>100	>100	3 5	5.05	12.5	25	12.5	>100	20
Conjugate	Squalamine		- 0	1 c	) ע	) /	۰ ۰	. <del>.</del>	- <del>(</del> .	9 1	15	17

a represents ATCC No. 13880;

b represents ATCC No. 90028;

c reports on the data from the Proc. Natl. Acad. Sci., supra, as the compound was not available to be directly compared with the remainder of the compounds reported herein; and

ND indicates the assay was not done

K<sub>50</sub> as used in the above table represents the concentration of compound that is required to induce the release of 50% of the hemoglobin that is contained with 3 X 10<sup>7</sup> sheep red blood cells at 37° C after a 60 minute period [specific protocols for these tests were similar to those reported in Biochem. Pharm. 37:827 (1988)]. The numbers in parentheses correspond to accession numbers with the American Type Culture Collection. In addition to the results reported in the Table, compound 2 was also tested against clinical isolates of *Cryptococcus neoformans* and *Aspergillus fumigatus* and gave MIC values of 3.13 and 12.5 μg/ml, respectively.

As evidenced by the data in Table 1, the compounds according to the present invention exhibit potent antimicrobial activity against a broad spectrum of microorganisms.

The compounds according to the present invention, based upon the scientifically recognized correlation between the assays reported in Table 1 and the therapeutic activity that can be expected when these compounds are administered to mammals, are potentially useful in the treatment of microbial disease states in mammals when administered to the mammal in need of therapy in amounts of from about 1 mg to about 100 mg per kg of body weight per day. Of course, the exact dose levels given on a daily basis is meant to be adapted by the physician to provide the optimum therapeutic response. For example, several divided doses may be administered daily, or the dose may be proportionally increased or reduced as indicated by the exigencies of the individual therapeutic situation. The compounds according to the present invention may be administered as the free compound, or as a pharmaceutically acceptable salt thereof, or as an active agent in a pharmaceutical formulation that includes such carriers, fillers, extenders, dispersants, creams, gels and solutions as is common in the pharmaceutical formulatory arts. The compounds according to the present invention may be formulated for all modes of application including, for example, modes that encompass topical, intravenous, oral, intraperitoneal, subcutaneous, vaginal,

WO 96/38464 PCT/US96/04851

ocular or intramuscular routes of administration. These modes may be, for example, in the form of capsules, powders, tablets, gels, creams; ointments, or liquids for injection or topical application. In addition the compounds according to the present invention may be compounded with other medicaments, or used in conjunction with devices such as, for example, condoms for use in vaginal application.

Thus while I have illustrated and described the preferred embodiment of my invention, it is to be understood that this invention is capable of variation and modification, and I therefore do not wish to be limited to the precise terms set forth, but desire to avail myself of such changes and alterations which may be made for adapting the invention to various usages and conditions. Thus, such variations and modifications are properly intended to be within the full range of equivalents, and therefore within the purview of the following claims.

Having thus described my invention and the manner and a process of making and using it in such full, clear, concise and exact terms so as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same;

18

I claim:

1. A sterol conjugate compound of the formula

wherein each R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> is individually selected from the group consisting of H, OH and OSO<sub>3</sub>H; and wherein Y is NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHC<sub>1</sub>, or NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>.

2. A compound according to claim 1 which is

wherein Y is selected from the group consisting of NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHC<sub>1</sub>, and NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHC<sub>2</sub>, and wherein X is selected from the group consisting of H and SO<sub>3</sub>H.

- 3. A compound according to Claim 2 wherein Y is NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>.
  - 4. The compound according to Claim 3 wherein X is H.
  - 5. The compound according to Claim 3 wherein X is SO<sub>3</sub>H.
- 6. A compound according to Claim 2 wherein Y is NHCH2CH2CH2CH2NH2.

- 7. The compound according to Claim 6 wherein X is H.
- 8. The compound according to Claim 6 wherein X is SO<sub>3</sub>H.
- 9. A compound according to Claim 2 wherein Y is NHCH2CH2NHCH2CH2NHCH2CH2NHCH2.
  - 10. The compound according to Claim 9 wherein X is H.
  - 11. The compound according to Claim 9 wherein X is SO<sub>3</sub>H.
  - 12. The compound according to Claim 1 which is

wherein Y is selected from the group consisting of NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, and NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>, and wherein X is selected from the group consisting of H and SO<sub>3</sub>H.

13. The compound according to Claim 1 which is

wherein Y is selected from the group consisting of NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, and NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub> and wherein X is selected from the group consisting of H and SO<sub>3</sub>H.

14. The compound according to Claim 1 which is

wherein X is selected from the group consisting of H, OSO<sub>3</sub>H, and OH, and Y is selected from the group consisting of NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub> or NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>.

15. A compound according to Claim 1 which is

wherein Y is selected from the group consisting of NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, and NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>, and wherein X is selected from the group consisting of H and SO<sub>3</sub>H.

16. A compound according to Claim 1 which is

wherein Y is selected from the group consisting of NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, and

NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, and wherein X is selected from the group consisting of H and SO<sub>3</sub>H.

- 17. A compound according to Claim 12 wherein Y is NH(CH2)3NH(CH2)4NH(CH2)3NH2.
  - 18. The compound according to Claim 17 wherein X is H.
  - 19. The compound according to Claim 17 wherein X is SO<sub>3</sub>H.
- 20. A compound according to Claim 12 wherein Y is NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>.
  - 21. The compound according to Claim 20 wherein X is H.
  - 22. The compound according to Claim 20 wherein X is SO<sub>3</sub>H.
- 23. A compound according to Claim 12 wherein Y is NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>.
  - 24. The compound according to Claim 23 wherein X is H.
  - 25. The compound according to Claim 23 wherein X is SO<sub>3</sub>H.
- 26. A compound according to Claim 13 wherein Y is  $NH(CH_2)3NH(CH_2)4NH(CH_2)3NH_2$ .
  - 27. The compound according to Claim 26 wherein X is H.
  - 28. The compound according to Claim 26 wherein X is SO<sub>3</sub>H.
- 29. A compound according to Claim 13 wherein Y is NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>.
  - 30. The compound according to Claim 29 wherein X is H.
  - 31. The compound according to Claim 29 wherein X is SO<sub>3</sub>H.
- 32. A compound according to Claim 13 wherein Y is NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>.
  - 33. The compound according to Claim 32 wherein X is H.
  - 34. The compound according to Claim 32 wherein X is SO<sub>3</sub>H.
- 35. A compound according to Claim 14 wherein Y is NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>.
  - 36. The compound according to Claim 35 wherein X is H.
  - 37. The compound according to Claim 35 wherein X is SO<sub>3</sub>H.

- 38. A compound according to Claim 14 wherein Y is NHCH2CH2CH2CH2NH2.
  - 39. The compound according to Claim 38 wherein X is H.
  - 40. The compound according to Claim 38 wherein X is SO<sub>3</sub>H.
- 41. A compound according to Claim 14 wherein Y is NHCH2CH2NHCH2CH2NHCH2CH2NHC.
  - 42. The compound according to Claim 41 wherein X is H.
  - 43. The compound according to Claim 41 wherein X is SO<sub>3</sub>H.
- 44. A compound according to Claim 15 wherein Y is NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>.
  - 45. The compound according to Claim 44 wherein X is H.
  - 46. The compound according to Claim 44 wherein X is SO<sub>3</sub>H.
- 47. A compound according to Claim 15 wherein Y is NHCH2CH2CH2NH2.
  - 48. The compound according to Claim 47 wherein X is H.
  - 49. The compound according to Claim 47 wherein X is SO<sub>3</sub>H.
- 50. A compound according to Claim 15 wherein Y is NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>.
  - 51. The compound according to Claim 50 wherein X is H.
  - 52. The compound according to Claim 50 wherein X is SO<sub>3</sub>H.
- 53. A compound according to Claim 16 wherein Y is NH(CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>4</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>.
  - 54. The compound according to Claim 53 wherein X is H.
  - 55. The compound according to Claim 53 wherein X is SO<sub>3</sub>H.
- 56. A compound according to Claim 16 wherein Y is NHCH2CH2CH2CH2NH2.
  - 57. The compound according to Claim 56 wherein X is H.
  - 58. The compound according to Claim 56 wherein X is SO<sub>3</sub>H.
- 59. A compound according to Claim 16 wherein Y is NHCH2CH2NHCH2CH2NHCH2CH2NHC.

WO 96/38464 PCT/US96/04851

23

- 60. The compound according to Claim 59 wherein  $\boldsymbol{X}$  is  $\boldsymbol{H}$ .
- 61. The compound according to Claim 59 wherein X is SO<sub>3</sub>H.

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/04851

F		L.					
A. CLASSIFICATION OF SUBJECT MATTER  IPC(6) : CO7J 7/00, 9/00, 41/00  US CL : 552/554, 557, 600, 606							
	According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIEI	LDS SEARCHED						
Minimum d	ocumentation searched (classification system followed	d by classification symbols)					
U.S. :	552/554, 557, 600, 606						
Documenta	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched .						
Electronic o	data base consulted during the international search (na	ame of data base and, where practicable	, search terms used)				
C. DOC	CUMENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.				
Α	US, A, 5,122,520 (AZRIA ET AL) document.	16 June 1992, see entire	1-61				
А	Steroids, Volume 37, No. 4, issued April 1981, A. Hill et al, "The Preparation of Amino Bile Acid Derivatives," pages 393-398.						
Α	JP, A2, 3-99095 (HEISEI ET AL) document.	24 April 1991, see entrie	1-61				
А	JP, A2, 4-247097 (HEISEI ET AL) entire document.	03 September 1992, see	1-61				
А	DE, A1, 4000397 (HOECHST AG) document.	11 July 1991, see entire	1-61				
Furth	ner documents are listed in the continuation of Box C	See patent family annex.					
	ecial categories of cited documents:	"T" later document published after the integrated date and not in conflict with the applic	ernational filing date or priority				
	cument defining the general state of the art which is not considered be of particular relevance	principle or theory underlying the inv	rention				
	rlier document published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be considered.					
cit	cument which may throw doubts on priority claim(s) or which is ed to establish the publication date of another citation or other	when the document is taken alone  "Y"  document of particular relevance: the					
*O* do	ecial reason (as specified) cument referring to an oral disclosure, use, exhibition or other cans	"Y" document of particular relevance; the considered to involve an inventive combined with one or more other such the property of the property of the property of the property of the particular than the part	step when the document is th documents, such combination				
P' document published prior to the international filing date but later than *&* document member of the same patent family the priority date claimed							
Date of the	actual completion of the international search	Date of mailing of the international sea	arch report				
11 JULY	1996	/ 25 JUL 1	1996 /				
Commissio Box PCT	Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT KIMBERLY J. PRIOR						
	n, D.C. 20231 Io. (703) 305-3230	Telephone Ng. (703) 308-1235					

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/04851

Box I C	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inter	national report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
. 🔲	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
².	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
	bservations where unity of invention is lacking (Continuation of item 2 of first sheet)
	national Searching Authority found multiple inventions in this international application, as follows:
Ple	ase See Extra Sheet.
X	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
emark o	n Protest
	No protest accompanied the payment of additional search fees.

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/04851

#### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

I.Pregnane derivatives, Claims 2-11

II. Deoxycholic acid derivatives, Claims 12, 17-28

III. Cholic acid derivatives, Claims 13, 29-34

IV.Lithocholic acid derivatives, Claims 14, 35-43

V. Hydeoxycholic acid derivatives, Claims 15, 44-52

VI. Chenodeoxycholic acid derivatives, Claims 16, 53-61

The following claims are generic: Claim 1

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The compounds have different structures. The pregnane species corresponding to the first species are known in the art for use as progestiometic hormones. Each of the second through sixth species are bile acid derivatives which are known to have varying effects on the cholinergic receptor pathways.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The compoundshavedifferentstructures. The pregnane species corresponding to the first species are known in the art for use as progestiometic hormones. Each of the second through sixth species are bile acid derivatives which are known to have varying effects on the cholinergic receptor pathways.